

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JDH 京东健康

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

INSIDE INFORMATION

UNAUDITED UPDATE ON THE 2025 THIRD QUARTER

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

During the third quarter of 2025, JD Health entered into strategic cooperation agreements with leading pharmaceutical companies, including Eli Lilly, Innovent Biologics, Eisai China, and Bayer China. We also debuted a range of innovative drugs online, such as Eisai’s originator drug DAYVIGO (達衛可[®]) (Lemborexant Tablets), Hengrui Pharma’s dry eye treatment Heng Qin (恒沁[®]) (Perfluorohexyloctane Eye Drops), and Bayer’s Talcid (達喜[®]) Lactulose, further solidifying JD Health’s position as “the Leading Online Marketplace for New and Specialty Medicine Launches.” Beyond pharmaceuticals, JD Health also hosted the initial launch for various nutrition and health supplement products, including Haleon’s next-generation Centrum Silver (銀善存[®]) vitamins and Sainte’s Teai Benjia (特愛本佳), China’s first special medical purpose formula for phenylketonuria.

In September 2025, JD Health partnered with several medical device brands, including Yuwell, Sinocare, and MicroTech, to establish the intelligent interconnected ecosystem alliance. Leveraging JD Health’s AI agents, the alliance aims to build an integrated, full-cycle smart blood glucose management system covering monitoring, analysis, intervention and tracking. Looking ahead, the collaboration will expand to blood pressure, ECG, respiratory oxygenation, and additional health devices, creating a comprehensive service ecosystem spanning disease prevention to chronic disease management that meets users’ long-term health management needs.

In September 2025, JD Health signed a cooperation agreement with Union Hospital of Huazhong University of Science and Technology's Tongji Medical College to jointly establish a nationally leading intelligent outpatient service platform. Together, both parties will drive the broader application of JD Health's "JOY DOC" (京東卓醫) AI products in offline hospital outpatient service scenarios, creating a full-process AI companion system to provide patients with a more convenient medical experience. Going forward, the parties will also deepen cooperation in areas such as online health services, jointly exploring new models for "Internet + healthcare" services.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue, operating income and profit of the Group for the three months ended September 30, 2025 together with comparative figures for the corresponding period of 2024:

	Three months ended		
	September 30,		
	2025	2024	Change
	RMB'000	RMB'000	(%)
	(Unaudited)	(Unaudited)	
Revenue	17,119,726	13,302,050	28.7
Operating income ⁽¹⁾	1,243,290	551,733	125.3
Non-IFRS operating income ⁽²⁾	1,377,755	861,809	59.9
Profit for the period	1,838,503	932,208	97.2
Non-IFRS profit for the period ⁽³⁾	1,902,237	1,335,616	42.4

(1) Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal, except for impairment losses of a certain asset that is non-operating in nature.

(2) We define "non-IFRS operating income" as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

(3) We define "non-IFRS profit" as profit for the period, excluding share-based payment expenses, fair value changes for financial assets and liabilities at fair value through profit or loss except for wealth management products, impairment losses of a certain asset, and tax effects on non-IFRS adjustments for the period. We exclude these items because they are non-operating in nature, not indicative of our core operating results and business outlook, or they do not generate any cash outflows.

The above information is based on the board (the "**Board**") of directors (the "**Directors**") of the Company's preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group's financial result. The said information and data have not been audited or reviewed by the Company's auditors and may be subject to change and adjustment.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Dong Cao
Executive Director

Hong Kong, November 13, 2025

As of the date of this announcement, the Board comprises Mr. Dong Cao as the executive Director, Mr. Richard Qiangdong Liu as non-executive Director, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.